Treatment of acromegaly improves quality of life, measured by AcroQol.

2.50
Hdl Handle:
http://hdl.handle.net/10541/71973
Title:
Treatment of acromegaly improves quality of life, measured by AcroQol.
Authors:
Paisley, Angela N; Rowles, Susannah V; Roberts, Margaret E; Webb, Susan M; Badia, Xavier; Prieto, L; Shalet, Stephen M; Trainer, Peter J
Abstract:
BACKGROUND: AcroQol is a disease-generated questionnaire, developed to assess quality of life (QOL) in patients with acromegaly. We have previously demonstrated severely impaired QOL in patients with acromegaly and the value of AcroQol in measuring QOL in a cross-sectional study compared with the non-disease-specific generic tools 'Psychological general wellbeing schedule' (PGWBS) and EuroQol (EQ-5D), and the disease-specific signs and symptoms score (SSS). AIM, SUBJECTS AND METHODS: We re-evaluated these tools in a longitudinal study of 56 of the previously reported patients (33 male, mean age 55 +/- 15 years), in order to determine change in QOL over time and the effect of different treatment modalities. Data were analysed using Spearman's correlation tests. RESULTS: Baseline median IGF-I was 354 ng/ml (range 48-899) and at re-evaluation 217 ng/ml (60-594) (P < 0.001) [median time interval 608 days (113-1136)]. Analysis of change in IGF-I levels and AcroQol scores demonstrated a significant negative correlation (i.e. a reduction in IGF-I being associated with improved overall QOL (r = -0.36, P = 0.006). Significant negative correlations were also seen in the physical (r = -0.33, P = 0.01), psychological (r = -0.37, P = 0.005) and appearance (r = -0.42, P = 0.001) AcroQol subdomains. No correlations were seen between change in IGF-I and change in overall PGWBS score or subdomains, SSS or EQ-5D. CONCLUSIONS: In summary, of the tools studied we have demonstrated AcroQol to be uniquely capable of detecting changes in QOL associated with treatment-induced improvement in the main biochemical marker of disease activity in patients with acromegaly. Further studies are required to evaluate the long-term biological significance of the changes seen in AcroQol.
Affiliation:
Department of Endocrinology, Christie Hospital, Wilmslow Road, Manchester, UK.
Citation:
Treatment of acromegaly improves quality of life, measured by AcroQol. 2007, 67 (3):358-62 Clin. Endocrinol.
Journal:
Clinical Endocrinology
Issue Date:
Sep-2007
URI:
http://hdl.handle.net/10541/71973
DOI:
10.1111/j.1365-2265.2007.02891.x
PubMed ID:
17555502
Type:
Article
Language:
en
ISSN:
0300-0664
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPaisley, Angela N-
dc.contributor.authorRowles, Susannah V-
dc.contributor.authorRoberts, Margaret E-
dc.contributor.authorWebb, Susan M-
dc.contributor.authorBadia, Xavier-
dc.contributor.authorPrieto, L-
dc.contributor.authorShalet, Stephen M-
dc.contributor.authorTrainer, Peter J-
dc.date.accessioned2009-06-30T13:53:04Z-
dc.date.available2009-06-30T13:53:04Z-
dc.date.issued2007-09-
dc.identifier.citationTreatment of acromegaly improves quality of life, measured by AcroQol. 2007, 67 (3):358-62 Clin. Endocrinol.en
dc.identifier.issn0300-0664-
dc.identifier.pmid17555502-
dc.identifier.doi10.1111/j.1365-2265.2007.02891.x-
dc.identifier.urihttp://hdl.handle.net/10541/71973-
dc.description.abstractBACKGROUND: AcroQol is a disease-generated questionnaire, developed to assess quality of life (QOL) in patients with acromegaly. We have previously demonstrated severely impaired QOL in patients with acromegaly and the value of AcroQol in measuring QOL in a cross-sectional study compared with the non-disease-specific generic tools 'Psychological general wellbeing schedule' (PGWBS) and EuroQol (EQ-5D), and the disease-specific signs and symptoms score (SSS). AIM, SUBJECTS AND METHODS: We re-evaluated these tools in a longitudinal study of 56 of the previously reported patients (33 male, mean age 55 +/- 15 years), in order to determine change in QOL over time and the effect of different treatment modalities. Data were analysed using Spearman's correlation tests. RESULTS: Baseline median IGF-I was 354 ng/ml (range 48-899) and at re-evaluation 217 ng/ml (60-594) (P < 0.001) [median time interval 608 days (113-1136)]. Analysis of change in IGF-I levels and AcroQol scores demonstrated a significant negative correlation (i.e. a reduction in IGF-I being associated with improved overall QOL (r = -0.36, P = 0.006). Significant negative correlations were also seen in the physical (r = -0.33, P = 0.01), psychological (r = -0.37, P = 0.005) and appearance (r = -0.42, P = 0.001) AcroQol subdomains. No correlations were seen between change in IGF-I and change in overall PGWBS score or subdomains, SSS or EQ-5D. CONCLUSIONS: In summary, of the tools studied we have demonstrated AcroQol to be uniquely capable of detecting changes in QOL associated with treatment-induced improvement in the main biochemical marker of disease activity in patients with acromegaly. Further studies are required to evaluate the long-term biological significance of the changes seen in AcroQol.en
dc.language.isoenen
dc.subjectQuality of Lifeen
dc.subjectQuestionnaireen
dc.subjectAcromegalyen
dc.titleTreatment of acromegaly improves quality of life, measured by AcroQol.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital, Wilmslow Road, Manchester, UK.en
dc.identifier.journalClinical Endocrinologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.